Closing Bell: Tesla Jumps on Robotaxi Rollout, Circle Rises, Hims & Hers Sinks | Stock Movers
June 23, 2025
1,224
2
0.16%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Bloomberg Podcasts Episodes Around June 23, 2025
See what was published immediately before and after this episode.
6:09Now PlayingClosing Bell: Tesla Jumps on Robotaxi Rollout, Circle Rises, Hims & Hers Sinks | Stock Movers
YouTube Description
as posted by the channelOn this episode of Stock Movers:
Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Scarlet Fu, Alix Steel, Carol Massar and Tim Stenovec.
- Tesla (TSLA) shares climbed after the automaker rolled out its long-promised driverless taxi service to a handful of riders, a modest debut for what Elon Musk sees as a transformative new business line. The first robotaxi trips were limited to a narrow portion of Tesla’s hometown of Austin on Sunday, with an employee sitting in the front passenger seat of each vehicle to monitor for safety. The carmaker hand-picked a friendly group of retail investors and social-media influencers to serve as initial riders and live-stream their trips.
- Circle (CRCL) shares extended gains for a third consecutive session after the Senate passed stablecoin legislation last week.
- Hims & Hers (HIMS) shares dropped following news that Novo Nordisk was scrapping a partnership with the upstart telehealth platform after less than two months. Hims, a telehealth platform, wasn’t stepping back enough from its practice of mass marketing off-brand imitations of the weight-loss medicine, Novo executives said.“The big issue with Hims is that we had an agreement that the mass compounding would stop and unfortunately it didn’t stop,” said Ludovic Helfgott, executive vice president of product and portfolio strategy at Novo, in an interview. “That’s why we ended the partnership.” In a post on X, Hims Chief Executive Officer Andrew Dudum called Novo executive comments “misleading.” He said Novo had been pressuring Hims to “steer patients to Wegovy regardless of whether it was clinically best for patients.”
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
Closing Bell: Tesla Jumps on Robotaxi Rollout, Circle Rises, Hims & Hers Sinks
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.